ERBB2 and breast cancer: In patients with HER2-positive breast cancer refractory to trastuzumab-based therapy, continuation of trastuzumab in the second-line setting has been shown to prolong survival, with such trastuzumab beyond progression (TBP) being an established strategy for this cancer [15,16].